Next Generation Sequencing for Hematological Malignancies

A Non-Invasive Alternative To Assess Your Tumor Derived Gene Alterations

Cerba Research is proud to offer a full range of next generation sequencing capabilities for your liquid tumors clinical trial specimens.

We have broad panel assays to cover for indications such as myeloproliferative syndrome, acute myeloid leukemia, myeloid tumors, lymphoproliferative syndromes and more.

Discover how we can help you to unlock the genomics information from your liquid tumor specimens.

Cerba Paris Comprehensive Hematological Malignancies Panels

Panel Name	Genes	Tumor Type	Instrument	TAT	Bone marrow	Peripheral blood
MPN Panel	15	Myeloproliferative neoplasms	NextSeq	15	X	X
MDS/CMML Panel	32	Myelodysplastic syndromes, CMML	NextSeq	15	X	X
AML Panel	36	Acute myeloid leukemia	NextSeq	15	X	X
Pan-myeloid Panel AML / MDS / CMML / MPN	40	Myeloid tumors, CMML, MDS	NextSeq	15	X	X
Mature Lymphoid Panel	10	Lymphoproliferative syndromes	NextSeq	15	X	X

Panel Name

Genes	15
Tumor Type	Myeloproliferative neoplasms
Instrument	NextSeq
TAT	15
Bone marrow	X
Peripheral blood	X
FFPE

Panel Name

Genes	32
Tumor Type	Myelodysplastic syndromes, CMML
Instrument	NextSeq
TAT	15
Bone marrow	X
Peripheral blood	X
FFPE

Panel Name

Genes	36
Tumor Type	Acute myeloid leukemia
Instrument	NextSeq
TAT	15
Bone marrow	X
Peripheral blood	X
FFPE

Panel Name

Genes	40
Tumor Type	Myeloid tumors, CMML, MDS
Instrument	NextSeq
TAT	15
Bone marrow	X
Peripheral blood	X
FFPE

Panel Name

Genes	10
Tumor Type	Lymphoproliferative syndromes
Instrument	NextSeq
TAT	15
Bone marrow	X
Peripheral blood	X
FFPE

Cerba Research Liquid Tumor NGS Landscape

Benefit from our capabilities and expertise to obtain the dataset you need for your liquid tumor clinical trial